1503 related articles for article (PubMed ID: 29462379)
21. The long-term consequences of antibiotic therapy: Role of colonic short-chain fatty acids (SCFA) system and intestinal barrier integrity.
Holota Y; Dovbynchuk T; Kaji I; Vareniuk I; Dzyubenko N; Chervinska T; Zakordonets L; Stetska V; Ostapchenko L; Serhiychuk T; Tolstanova G
PLoS One; 2019; 14(8):e0220642. PubMed ID: 31437166
[TBL] [Abstract][Full Text] [Related]
22. Inflammatory bowel disease is associated with increased gut-to-blood penetration of short-chain fatty acids: A new, non-invasive marker of a functional intestinal lesion.
Jaworska K; Konop M; Bielinska K; Hutsch T; Dziekiewicz M; Banaszkiewicz A; Ufnal M
Exp Physiol; 2019 Aug; 104(8):1226-1236. PubMed ID: 31243807
[TBL] [Abstract][Full Text] [Related]
23. Increased Expression of DUOX2 Is an Epithelial Response to Mucosal Dysbiosis Required for Immune Homeostasis in Mouse Intestine.
Grasberger H; Gao J; Nagao-Kitamoto H; Kitamoto S; Zhang M; Kamada N; Eaton KA; El-Zaatari M; Shreiner AB; Merchant JL; Owyang C; Kao JY
Gastroenterology; 2015 Dec; 149(7):1849-59. PubMed ID: 26261005
[TBL] [Abstract][Full Text] [Related]
24. Immunopathology of inflammatory bowel disease.
Wallace KL; Zheng LB; Kanazawa Y; Shih DQ
World J Gastroenterol; 2014 Jan; 20(1):6-21. PubMed ID: 24415853
[TBL] [Abstract][Full Text] [Related]
25. Microbiota-derived butyrate regulates intestinal inflammation: Focus on inflammatory bowel disease.
Couto MR; Gonçalves P; Magro F; Martel F
Pharmacol Res; 2020 Sep; 159():104947. PubMed ID: 32492488
[TBL] [Abstract][Full Text] [Related]
26. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis.
Yu LC
J Biomed Sci; 2018 Nov; 25(1):79. PubMed ID: 30413188
[TBL] [Abstract][Full Text] [Related]
27. Recipe for IBD: can we use food to control inflammatory bowel disease?
Witkowski M; Witkowski M; Gagliani N; Huber S
Semin Immunopathol; 2018 Feb; 40(2):145-156. PubMed ID: 29124320
[TBL] [Abstract][Full Text] [Related]
28. Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences.
Salem F; Kindt N; Marchesi JR; Netter P; Lopez A; Kokten T; Danese S; Jouzeau JY; Peyrin-Biroulet L; Moulin D
United European Gastroenterol J; 2019 Oct; 7(8):1008-1032. PubMed ID: 31662859
[TBL] [Abstract][Full Text] [Related]
29. [Inflammatory bowel diseases and enteric microbiota].
Kim JM
Korean J Gastroenterol; 2010 Jan; 55(1):4-18. PubMed ID: 20098062
[TBL] [Abstract][Full Text] [Related]
30. The Microbiota and the Immune Response: What Is the Chicken and What Is the Egg?
Fritsch J; Abreu MT
Gastrointest Endosc Clin N Am; 2019 Jul; 29(3):381-393. PubMed ID: 31078242
[TBL] [Abstract][Full Text] [Related]
31. Gut-Liver Physiomimetics Reveal Paradoxical Modulation of IBD-Related Inflammation by Short-Chain Fatty Acids.
Trapecar M; Communal C; Velazquez J; Maass CA; Huang YJ; Schneider K; Wright CW; Butty V; Eng G; Yilmaz O; Trumper D; Griffith LG
Cell Syst; 2020 Mar; 10(3):223-239.e9. PubMed ID: 32191873
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-15 promotes intestinal dysbiosis with butyrate deficiency associated with increased susceptibility to colitis.
Meisel M; Mayassi T; Fehlner-Peach H; Koval JC; O'Brien SL; Hinterleitner R; Lesko K; Kim S; Bouziat R; Chen L; Weber CR; Mazmanian SK; Jabri B; Antonopoulos DA
ISME J; 2017 Jan; 11(1):15-30. PubMed ID: 27648810
[TBL] [Abstract][Full Text] [Related]
33. The Impact of Dietary Sphingolipids on Intestinal Microbiota and Gastrointestinal Immune Homeostasis.
Rohrhofer J; Zwirzitz B; Selberherr E; Untersmayr E
Front Immunol; 2021; 12():635704. PubMed ID: 34054805
[TBL] [Abstract][Full Text] [Related]
34. The Role of Succinate in the Regulation of Intestinal Inflammation.
Connors J; Dawe N; Van Limbergen J
Nutrients; 2018 Dec; 11(1):. PubMed ID: 30583500
[TBL] [Abstract][Full Text] [Related]
35. Exploring the Molecular Mechanisms Underlying the Protective Effects of Microbial SCFAs on Intestinal Tolerance and Food Allergy.
Luu M; Monning H; Visekruna A
Front Immunol; 2020; 11():1225. PubMed ID: 32612610
[TBL] [Abstract][Full Text] [Related]
36. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
[TBL] [Abstract][Full Text] [Related]
37. Gut biofilm forming bacteria in inflammatory bowel disease.
Srivastava A; Gupta J; Kumar S; Kumar A
Microb Pathog; 2017 Nov; 112():5-14. PubMed ID: 28942174
[TBL] [Abstract][Full Text] [Related]
38. The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review.
Aldars-García L; Marin AC; Chaparro M; Gisbert JP
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802883
[TBL] [Abstract][Full Text] [Related]
39. Metabolism at the centre of the host-microbe relationship.
Maslowski KM
Clin Exp Immunol; 2019 Aug; 197(2):193-204. PubMed ID: 31107965
[TBL] [Abstract][Full Text] [Related]
40. Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice.
Hoffmann TW; Pham HP; Bridonneau C; Aubry C; Lamas B; Martin-Gallausiaux C; Moroldo M; Rainteau D; Lapaque N; Six A; Richard ML; Fargier E; Le Guern ME; Langella P; Sokol H
ISME J; 2016 Feb; 10(2):460-77. PubMed ID: 26218241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
